We are live on ! Find out more
CCM

Cutter Capital Management Portfolio holdings

AUM $230M
1-Year Est. Return 11.53%
This Fund
S&P 500
This Quarter Est. Return
+1.97%
1 Year Est. Return
+11.53%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$331M
AUM Growth
+$69.8M
Cap. Flow
+$69.3M
Cap. Flow %
20.92%
Top 10 Hldgs %
55.35%
Holding
39
New
13
Increased
9
Reduced
5
Closed
12

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.6M
2
AMGN icon
Amgen
AMGN
+$18.9M
3
KVUE icon
Kenvue
KVUE
+$18.6M
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$15.6M
5
CYTK icon
Cytokinetics
CYTK
+$14.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$24.2M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$15.7M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$12.2M
4
HALO icon
Halozyme
HALO
+$10.4M
5
EXEL icon
Exelixis
EXEL
+$9.46M

Sector Composition

Rank Sector Weight
1 Healthcare 93.78%
2 Consumer Staples 5.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$11.4B
$22.5M 6.8%
273,533
+98,533
+56% +$8.2M
MRK icon
2
Merck
MRK
$307B
$21.7M 6.56%
+175,600
New +$22.6M
GILD icon
3
Gilead Sciences
GILD
$165B
$20.1M 6.07%
292,959
+27,523
+10% +$1.84M
AMGN icon
4
Amgen
AMGN
$197B
$20.1M 6.06%
+64,201
New +$18.9M
RPRX icon
5
Royalty Pharma
RPRX
$25.4B
$18.3M 5.51%
692,300
+280,760
+68% +$7.78M
BIIB icon
6
Biogen
BIIB
$29.5B
$17.8M 5.37%
76,726
+24,726
+48% +$5.37M
KVUE icon
7
Kenvue
KVUE
$36.5B
$17.5M 5.27%
+960,400
New +$18.6M
INSM icon
8
Insmed
INSM
$23.2B
$15.3M 4.6%
227,637
+300
+0.1% +$11.6K
LEGN icon
9
Legend Biotech
LEGN
$4.49B
$15.2M 4.59%
343,130
+263,300
+330% +$12.1M
RARE icon
10
Ultragenyx Pharmaceutical
RARE
$2.81B
$15M 4.53%
+365,000
New +$15.6M
TEVA icon
11
Teva Pharmaceuticals
TEVA
$36.1B
$14.8M 4.47%
911,900
-223,810
-20% -$3.45M
SRPT icon
12
Sarepta Therapeutics
SRPT
$1.78B
$14.1M 4.26%
89,379
-5,000
-5% -$642K
CYTK icon
13
Cytokinetics
CYTK
$10.7B
$12.8M 3.87%
+236,900
New +$14.3M
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.32B
$12.2M 3.68%
1,975,298
-130,161
-6% -$718K
CRSP icon
15
CRISPR Therapeutics
CRSP
$4.63B
$10.9M 3.29%
201,497
+81,312
+68% +$4.7M
ACLX
16
DELISTED
Arcellx
ACLX
$10.3M 3.12%
187,000
+80,000
+75% +$4.35M
AVDL
17
DELISTED
Avadel Pharmaceuticals
AVDL
$10.3M 3.11%
733,001
+191,075
+35% +$3.11M
HRMY icon
18
Harmony Biosciences
HRMY
$1.94B
$8.92M 2.69%
+295,771
New +$8.89M
AVTR icon
19
Avantor
AVTR
$7.28B
$8.48M 2.56%
+400,000
New +$9.63M
VERA icon
20
Vera Therapeutics
VERA
$2.66B
$8.32M 2.51%
+230,000
New +$9.12M
BBIO icon
21
BridgeBio Pharma
BBIO
$15.8B
$7.9M 2.38%
+311,700
New +$8.52M
IONS icon
22
Ionis Pharmaceuticals
IONS
$8.75B
$7.63M 2.3%
160,166
-129,200
-45% -$5.3M
ELVN icon
23
Enliven Therapeutics
ELVN
$3.69B
$5.21M 1.57%
+222,985
New +$4.69M
PFE icon
24
Pfizer
PFE
$141B
$5.18M 1.56%
+185,200
New +$5.1M
EOLS icon
25
Evolus
EOLS
$365M
$5.05M 1.52%
+465,300
New +$5.72M
1
2

Similar funds

SAM
Selway Asset Management $242M AUM 7.7% 1-Year Est. Return
CW
Cook Wealth Raleigh, North Carolina $206M AUM 4.73% 1-Year Est. Return
IAM
Impact Asset Management Vienna $255M AUM
BCM
BluePointe Capital Management Menlo Park, California $262M AUM 9.24% 1-Year Est. Return
CWM
Cahill Wealth Management Portage, Michigan $196M AUM 8.5% 1-Year Est. Return
RI
Redwood Investments Boston, Massachusetts $267M AUM 11.99% 1-Year Est. Return
LA
Lane & Associates Moorestown, New Jersey $186M AUM 5.34% 1-Year Est. Return
GWA
GGM Wealth Advisors Baltimore, Maryland $180M AUM 10.57% 1-Year Est. Return

Cutter Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Cutter Capital Management held 39 positions worth $331M, up 27% from $262M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Cutter Capital Management deployed $69.3M of net new capital in Q2 2024, opening 13 new positions and adding to 9 existing holdings. Its largest new stake was Merck: 175,600 shares worth $21.7M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 99% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Perrigo, an estimated $6.53M trimmed.

  • Cutter Capital Management's largest Q2 2024 buy was Merck: 175,600 shares worth $21.7M.
  • Cutter Capital Management added most to Legend Biotech in Q2 2024, an estimated $12.1M increase.
  • Cutter Capital Management's biggest Q2 2024 reduction was Perrigo, cutting an estimated $6.53M.
  • Cutter Capital Management fully exited Bristol-Myers Squibb in Q2 2024, selling an estimated $24.2M.
  • Cutter Capital Management's ten largest holdings make up 55% of its $331M portfolio in Q2 2024.
  • Cutter Capital Management opened 13 new positions and closed 12 in Q2 2024.
  • Cutter Capital Management's portfolio value rose 27% quarter-over-quarter to $331M.

Based on Cutter Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.